AbCellera Biologics Inc. (FRA:8QQ)

Market Cap	1.05B +87.5%
Revenue (ttm)	63.99M +160.6%
Net Income	-124.70M
EPS	-0.42
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	477
Open	3.390
Previous Close	3.540
Day's Range	3.390 - 3.390
52-Week Range	1.747 - 5.780
Beta	n/a
RSI	58.45
Earnings Date	May 11, 2026

About AbCellera Biologics

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lil...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2012
• Employees: 562
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 8QQ

Financial Performance

In 2025, AbCellera Biologics's revenue was $75.13 million, an increase of 160.56% compared to the previous year's $28.83 million. Losses were -$146.41 million, -10.10% less than in 2024.

Financial numbers in USD